BioAtla Q2 net loss $21.1M; cash to Q3 2025; Fast Track for ozuriftamab vedotin

BioAtla, Inc.

2024-Q2 EPS reported -$0.92

Net loss of $21.1M for Q2 2024 vs $35.8M in Q2 2023; R&D expenses fell to $16.2M from $31.0M.
Cash and equivalents $61.7M as of June 30, 2024, expected to fund operations through Q3 2025.
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track by FDA for SCCHN; FDA meeting for registrational trial expected in 2H 2024.
Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 in NSCLC shows OS trend in mutated KRAS; responses across G12A, G12C, G12V.
Evalstotug (CAB-CTLA-4) combined Phase 1/2 safety: low grade 3 irAEs (4/40); Phase 2 melanoma data on track for 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.